NCT00657644已完成3 期
Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 130
- 主要终点
- Erectile Function (EF) domain score
研究概览
简要总结
To find out more information on how effective and safe vardenafil is at treating impotence in men living in Russia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males with ED according to the NIH definition (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance) for at least 3 months.
- •Heterosexual relationship
- •Age range: 18 years and older
- •Documented written Informed Consent
- •The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary "Was sexual activity initiated with the intention of intercourse?") on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"] "Were you able to achieve at least partial erection (some enlargement of the penis)?", "Were you able to insert your penis in your partner's vagina?" and "Did your erection last long enough for you to have successful intercourse?".
排除标准
- •Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
- •Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) that in the opinion of the Investigator would significantly impair erectile function
- •Primary hypoactive sexual desire
- •Spinal cord injury
- •History of surgical prostatectomy (excluding TURP).
- •Retinitis pigmentosa
- •History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
- •History of positive test for HIV.
- •Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
- •Clinically significant chronic hematological disease, which may lead to priapism such as sickle cell anemia and leukemia.
- •Bleeding disorder.
- •Significant active peptic ulceration.
- •Unstable angina pectoris
- •History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
- •Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm).
- •Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg)
- •NYHA Class III and IV heart failure
- •Symptomatic postural hypotension within 6 months of visit
- •History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).
- •Concomitant Medication:
- •Subjects who are taking nitrates or nitric oxide donors.
- •Subjects who are taking anti-androgens
- •Subjects who are taking androgens.
- •Subjects who take anticoagulants, except for antiplatelet agents.
- •Subjects who have received any investigational drug (including placebo) within 30 days of visit 1.
- •Use of any treatment for ED within the 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
- •Subjects who are taking the following potent inhibitors of cytochrome P- 450 3A4: HIV protease inhibitors such as ritonavir or indinavir, the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
- •Subjects who are taking alpha-blockers.
- •Abnormal Laboratory Values:
- •Subjects who have a serum total testosterone level greater than 25% below the lower limit of normal according to the range of the testing laboratory
- •Subjects with a serum creatinine >3.0 mg/dl
- •Elevation of AST and/or ALT >3X the ULN.
- •Diabetic subjects with an HbA1c >12%.
研究组 & 干预措施
Arm 1
Experimental
干预措施: Levitra (Vardenafil, BAY38-9456) (Drug)
结局指标
主要结局
Erectile Function (EF) domain score
时间窗: Week 12
次要结局
- Erectile Function (EF) domain score(Week 4, 8 and 12 Last Observation Carried Forward (LOCF))
- Haematology, Clinical Chemistry, Urinalysis(Week 12)
- IIEF domain scores(Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF))
- Premature termination, adverse events, laboratory abnormalities and concomitant medication usage(Week 4, 8 and 12)
- Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate(Week 12)
- Change from baseline of Erectile Function domain score(Week 4, 8 and 12 Last Observation Carried Forward (LOCF))
- Patient Diary Questions(Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF))
- Global Assessment Question (GAQ)(Week 4, 8, 12 and 12 Last Observation Carried Forward (LOCF))
研究者
相似试验
已完成
3 期
To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.Erectile DysfunctionNCT00661115Bayer173
已完成
3 期
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile DysfunctionErectile DysfunctionNCT00657033Bayer229
已完成
3 期
A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile DysfunctionErectile DysfunctionNCT00661700Bayer611
已完成
3 期
Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or HyperlipidemiaErectile DysfunctionNCT00668109Bayer614
已完成
4 期
BAY38-9456, 5/10/20mg, vs.Placebo in Erectile DysfunctionErectile DysfunctionNCT00665054Bayer160